mammoscreenproject.eu Análise do site para março 2026

Frequently Asked Questions on MammoScreen Frequently Asked Questions on MammoScreen DISCLAIMER The information provided on this webpage is for informational purposes only and does not constitute medical advice or an offer to participate in clinical trials. The study complies with applicable regulations, including the Medical Devices Regulation (EU) 2017/745 (MDR) and the In Vitro Diagnostic Devices Regulation (EU) 2017/746 (IVDR). For more details, please see the official registry website https://clinicaltrials.gov. The study is conducted in accordance with Regulation (EU) 536/2014 on clinical trials. DISCLAIMER Can I take part in the MammoScreen clinical study? MammoScreen clinical study will enrol 10,000 women already included in regional or national breast cancer screening programmes in Italy, Spain, Switzerland, Poland and Portugal. Ten clinical trial centers overall will be involved in the study.Women that fulfill the requirements to join the clinical trial will be thoroughly informed about all its aspects and asked to sign and informed consent before proceeding with the examination with MammoWave®.The only way to join the trial is that you fall within the screening programmes and you are appointed to one of the clinical trial centers carrying out the study. In this case, at the moment of your regular screening, you might be asked to take part to the MammoScreen study. The study cannot enroll spontaneous applications. How can I stay informed on the progress of MammoScreen project? You can follow MammoScreen on Facebook and LinkedIn, or you can subscribe to the newsletter to be always updated. In which way MammoScreen is making breast screening more friendly? MammoScreen aims at being as patient centric as possible and making every woman the subject of the screening process, helping women to have a better patient experience and increasing compliance and adherence to programs. Besides, MammoScreen will develop a modern, patient-facing app, to put patients and the